WO2001003719A3 - Combination therapy for conditions leading to bone loss - Google Patents

Combination therapy for conditions leading to bone loss Download PDF

Info

Publication number
WO2001003719A3
WO2001003719A3 PCT/US2000/018667 US0018667W WO0103719A3 WO 2001003719 A3 WO2001003719 A3 WO 2001003719A3 US 0018667 W US0018667 W US 0018667W WO 0103719 A3 WO0103719 A3 WO 0103719A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
inhibitors
combination therapy
bone loss
conditions leading
Prior art date
Application number
PCT/US2000/018667
Other languages
French (fr)
Other versions
WO2001003719A2 (en
WO2001003719A9 (en
Inventor
William J Boyle
David Lee Lacey
Frank J Calzone
Ming-Shi Chang
Giorgio Senaldi
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to AU60785/00A priority Critical patent/AU6078500A/en
Publication of WO2001003719A2 publication Critical patent/WO2001003719A2/en
Publication of WO2001003719A3 publication Critical patent/WO2001003719A3/en
Publication of WO2001003719A9 publication Critical patent/WO2001003719A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis. Methods of treatment are described using the polypeptides in conjunction with various agents, including IL-1 inhibitors, TNF-α inhibitors, and serine protease inhibitors.
PCT/US2000/018667 1999-07-09 2000-07-07 Combination therapy for conditions leading to bone loss WO2001003719A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60785/00A AU6078500A (en) 1999-07-09 2000-07-07 Combination therapy for conditions leading to bone loss

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35067099A 1999-07-09 1999-07-09
US09/350,670 1999-07-09
US45764799A 1999-12-09 1999-12-09
US09/457,647 1999-12-09

Publications (3)

Publication Number Publication Date
WO2001003719A2 WO2001003719A2 (en) 2001-01-18
WO2001003719A3 true WO2001003719A3 (en) 2002-02-21
WO2001003719A9 WO2001003719A9 (en) 2002-08-08

Family

ID=26996731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/018667 WO2001003719A2 (en) 1999-07-09 2000-07-07 Combination therapy for conditions leading to bone loss

Country Status (2)

Country Link
AU (1) AU6078500A (en)
WO (1) WO2001003719A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807795B2 (en) 1997-04-16 2010-10-05 Amgen Inc. Antibodies to osteoprotegerin binding proteins
US7923008B2 (en) 1997-04-16 2011-04-12 Amgen Inc. Methods for decreasing osteoclast formation or bone resorption using an antibody to osteoprotegerin binding protein

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
ES2144386T5 (en) 1996-12-23 2012-12-07 Immunex Corporation Ligand for the NF-kappa b receptor activator, the ligand is a member of the TNF superfamily
CA2781623A1 (en) 1997-04-15 1998-10-22 Daiichi Sankyo Company, Limited Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
AU762574B2 (en) 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
NZ511506A (en) 1998-10-28 2004-02-27 Sankyo Co Remedies for bone metabolic errors comprising OCIF
DE01973455T1 (en) 2000-09-22 2004-04-22 Immunex Corp., Seattle SCREENING PROCEDURE FOR AGONISTS AND ANTAGONISTS OF THE RECEPTOR ACTIVATOR OF NF-KAPPA B
CZ305653B6 (en) * 2001-01-29 2016-01-27 Merck Serono Sa Pharmaceutical composition
WO2002066063A1 (en) * 2001-02-23 2002-08-29 Nippon Organon K.K. Remedies for metabolic bone diseases
KR100942393B1 (en) 2001-05-25 2010-02-17 휴먼 게놈 사이언시즈, 인코포레이티드 Antibodies that immunospecifically bind to TRAIL receptors
AU2002341321A1 (en) * 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
TW200303757A (en) * 2002-03-01 2003-09-16 Sankyo Co A pharmaceutical composition
EP2314316A1 (en) 2002-04-05 2011-04-27 Amgen, Inc Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
JP2006521084A (en) 2002-12-10 2006-09-21 シェーリング−プラウ・リミテッド Canine RANKL and methods for preparing and using canine RANKL
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
CN101065401B (en) * 2004-12-13 2012-10-24 赛弗隆澳大利亚(Vic)私人有限公司 Osteoprotegerin variant proteins
EP2012819A2 (en) 2006-03-30 2009-01-14 The Research Foundation Of the City university of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021946A1 (en) * 1992-04-30 1993-11-11 Synergen, Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
EP0784093A1 (en) * 1995-12-22 1997-07-16 Amgen Inc. Osteoprotegerin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021946A1 (en) * 1992-04-30 1993-11-11 Synergen, Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
EP0784093A1 (en) * 1995-12-22 1997-07-16 Amgen Inc. Osteoprotegerin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARTIN T J ET AL: "Interleukins in the control of osteoclast differentiation.", CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, (1998) 8 (2) 107-23. REF: 143, XP000979080 *
ROODMAN G D: "ROLE OF CYTOKINES IN THE REGULATION OF BONE RESORPTION", CALCIFIED TISSUE INTERNATIONAL,NEW YORK, NY,US, vol. 53, no. SUPPL. 01, 1993, pages S94 - S98, XP000940463, ISSN: 0171-967X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807795B2 (en) 1997-04-16 2010-10-05 Amgen Inc. Antibodies to osteoprotegerin binding proteins
US7923008B2 (en) 1997-04-16 2011-04-12 Amgen Inc. Methods for decreasing osteoclast formation or bone resorption using an antibody to osteoprotegerin binding protein

Also Published As

Publication number Publication date
WO2001003719A2 (en) 2001-01-18
AU6078500A (en) 2001-01-30
WO2001003719A9 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
WO2001003719A3 (en) Combination therapy for conditions leading to bone loss
MX9706193A (en) Osteoprotegerin.
CA2184908A1 (en) Human osteoclast-derived cathepsin
AU1800295A (en) Calcitonin gene related peptide receptor
EP1717315A3 (en) Osteoprotegerin binding proteins and receptors
EP2277889A3 (en) Fusion proteins of albumin and interferon beta
EP1276756A1 (en) Albumin fusion proteins
EP2025682A3 (en) Human endokine alpha
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
WO2002097038A3 (en) Chemokine beta-1 fusion proteins
WO2003030821A3 (en) Albumin fusion proteins
EP1054958A4 (en) Human serine protease and serpin polypeptides
WO2001012776A3 (en) 18 human secreted proteins
WO2001034768A3 (en) 15 human secreted proteins
WO2000077026A8 (en) 49 human secreted proteins
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
WO2001062891A3 (en) 207 human secreted proteins
WO2000068247A3 (en) Serine proteases
WO2000050620A3 (en) Human endokine alpha and methods of use
WO2003029423A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2000001802A3 (en) Peptide antagonists of the human urokinase receptor and method for selecting them
WO2001064876A3 (en) Human schizophrenia gene
WO2000058339A3 (en) 50 human secreted proteins
WO2001012775A8 (en) 25 human secreted proteins
WO2000061624A8 (en) 48 human secreted proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/57-57/57, DRAWINGS, REPLACED BY NEW PAGES 1/60-60/60; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP